Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 355Neoplasms 252Carcinoma, Non-Small-Cell Lung 199Colorectal Neoplasms 181Lung Neoplasms 151Prostatic Neoplasms 150Carcinoma, Hepatocellular 127Leukemia, Myeloid, Acute 96Pancreatic Neoplasms 86Multiple Myeloma 82Neoplasm Metastasis 73Recurrence 72Uterine Cervical Neoplasms 68Rectal Neoplasms 68Ovarian Neoplasms 65Stomach Neoplasms 64Triple Negative Breast Neoplasms 59Squamous Cell Carcinoma of Head and Neck 57Brain Neoplasms 56Head and Neck Neoplasms 55Glioblastoma 55Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Small Cell Lung Carcinoma 48Melanoma 45Endometrial Neoplasms 43Disease 43Esophageal Neoplasms 42Hematologic Neoplasms 41Glioma 41Colonic Neoplasms 41

Interventions

darolutamide 1Rifampin 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Refractory or Relapsed Solid Tumors × 1 year × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡